Publication Name	World Journal of Gastroenterology
Manuscript ID	9389
Country	Italy

Received	2014-02-12 04:08
Peer-Review Started	2014-02-12 10:24
First Decision by Editorial Office Director
Return for Revision	2014-03-20 09:52
Revised	2014-04-29 17:33
Publication Fee Transferred
Second Decision by Editor	2014-06-05 10:49
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-06-05 10:54
Articles in Press	2014-06-05 11:25
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-08-28 15:36
Publish the Manuscript Online	2014-09-18 19:50

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Randomized Controlled Trial
Article Title	Otilonium bromide in irritable bowel syndrome: A dose-ranging randomized double-blind placebo-controlled trial
Manuscript Source	Unsolicited Manuscript
All Author List	Danuta Chmielewska-Wilkoń, Giorgio Reggiardo and Colin Gerard Egan
Funding Agency and Grant Number	Funding Agency Grant Number Menarini Group, Florence, Italy
Corresponding Author	Colin Gerard Egan, PhD, Primula Multimedia SRL, Via G. Ravizza 22/b Ospedaletto, 56121 Pisa, Italy. cegan@primulaedizioni.it
Key Words	Otilonium bromide; Irritable bowel syndrome; Spasmolytic; Acute treatment
Core Tip	Although previous trials have confirmed the efficacy of a single dose of otilonium bromide (OB) on well-defined endpoints in patients with irritable bowel syndrome (IBS), no study has specifically defined the optimal dosage of OB on standard IBS efficacy measures in a controlled cross-over design. Findings from this dose-ranging study demonstrate that OB at 40 and 80 mg can improve both individual and global clinical IBS symptoms compared to placebo over 4 wk. All doses of OB were well tolerated compared to placebo. Future long-term controlled trials on global efficacy measures will help reinforce findings from the present trial.
Publish Date	2014-09-18 19:50
Citation	Chmielewska-Wilkoń D, Reggiardo G, Egan CG. Otilonium bromide in irritable bowel syndrome: A dose-ranging randomized double-blind placebo-controlled trial. World J Gastroenterol 2014; 20(34): 12283-12291
URL	http://www.wjgnet.com/1007-9327/full/v20/i34/12283.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i34.12283

Full Article (PDF)	WJG-20-12283.pdf
Full Article (Word)	WJG-20-12283.doc
Manuscript File	9389-Review.docx
Answering Reviewers	9389-Answering reviewers.pdf
Biostatistics Review Certificate	Biostatistician_Review_Report_20140210174937.pdf
Copyright License Agreement	9389-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	Ethics_Committee_20140210174102.pdf
Peer-review Report	9389-Peer review(s).pdf
Scientific Misconduct Check	9389-CrossCheck.jpg
Scientific Editor Work List	9389-Scientific editor work list.pdf